Company / EPS (Diluted)
Prime Medicine, Inc. EPS (Diluted) History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$1.65
FY2024
5-year range
-$14.19 / -$1.65
FY2020-FY2024
Trend
+24.3%
vs FY2023
Sector context
#118 of 203
Health Care
What the data says
At $-1.65, Prime Medicine, Inc.'s eps (diluted) ranks #118 of 203 in the Health Care sector. EPS (Diluted) has increased for 3 consecutive years, from $-14.19 in FY2021 to $-1.65 in FY2024.
Based on SEC 10-K filings.
-1.65 in FY2024.
Improved from $-4.19 to $-1.65 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#118 of 203 in Health CareTop 58% of 203This company -$1.65 Sector average -$0.45
▼
-267.9% below sector average
Key checks
Key Insights
- Prime Medicine, Inc.'s eps (diluted) has grown for 3 consecutive years.
- In FY2024, eps (diluted) increased 24.3% year-over-year.
- Ranks #118 out of 203 companies in the Health Care sector.
- Lowest eps (diluted) in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -1.24 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$1.65 | +24.3% |
| FY2023 | -$2.18 | +48.0% |
| FY2022 | -$4.19 | +70.5% |
| FY2021 | -$14.19 | -642.9% |
| FY2020 | -$1.91 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026